Literature DB >> 29506610

Recurrent tuberculosis in the pre-elimination era.

A Rosser1, F M Marx2, M Pareek1.   

Abstract

Recurrent tuberculosis (TB), defined as TB that recurs after a patient has been considered cured, constitutes a challenge to TB control. In low TB burden countries, the underlying causes and consequences of recurrent TB are poorly understood. We conducted a literature review to summarise the evidence of recurrent TB in low-burden settings and to address current gaps in knowledge. We included peer-reviewed publications on studies conducted in countries with an estimated TB incidence of <100 cases per 100 000 population. The Newcastle-Ottawa scale was used to assess study quality. The review yielded 44 manuscripts, 39 of which were reports of observational studies and 5 of clinical trials. The median percentage of TB patients experiencing an episode of recurrent TB after treatment completion was 3.4% (interquartile range [IQR] 1.6-6.0, range 0.4-16.7) in studies with a median follow-up of 7.8 years (IQR 5-12, range 2-33). The median percentage of recurrences attributable to endogenous reactivation (rather than exogenous reinfection) was 81% (IQR 73.1-85.5, range 49-100). Commonly identified risk factors for recurrence in low-burden settings included infection by the human immunodeficiency virus, low socio-economic status, foreign birth and infection with drug-resistant TB. Current understanding of recurrence in low-burden settings is limited, in part due to substantial methodological differences between studies. Further research is required to delineate the mechanisms of TB recurrence, its health and clinical impact, as well as the implications for TB elimination efforts in low-burden countries.

Entities:  

Mesh:

Year:  2018        PMID: 29506610     DOI: 10.5588/ijtld.17.0590

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  10 in total

1.  An Update on Tuberculosis Vaccines.

Authors:  Radha Gopalaswamy; Selvakumar Subbian
Journal:  Methods Mol Biol       Date:  2022

2.  Clinical standards for the assessment, management and rehabilitation of post-TB lung disease.

Authors:  G B Migliori; F M Marx; N Ambrosino; E Zampogna; H S Schaaf; M M van der Zalm; B Allwood; A L Byrne; K Mortimer; R S Wallis; G J Fox; C C Leung; J M Chakaya; B Seaworth; A Rachow; B J Marais; J Furin; O W Akkerman; F Al Yaquobi; A F S Amaral; S Borisov; J A Caminero; A C C Carvalho; D Chesov; L R Codecasa; R C Teixeira; M P Dalcolmo; S Datta; A-T Dinh-Xuan; R Duarte; C A Evans; J-M García-García; G Günther; G Hoddinott; S Huddart; O Ivanova; R Laniado-Laborín; S Manga; K Manika; A Mariandyshev; F C Q Mello; S G Mpagama; M Muñoz-Torrico; P Nahid; C W M Ong; D J Palmero; A Piubello; E Pontali; D R Silva; R Singla; A Spanevello; S Tiberi; Z F Udwadia; M Vitacca; R Centis; L D Ambrosio; G Sotgiu; C Lange; D Visca
Journal:  Int J Tuberc Lung Dis       Date:  2021-10-01       Impact factor: 3.427

Review 3.  Breathing Back Better! A State of the Art on the Benefits of Functional Evaluation and Rehabilitation of Post-Tuberculosis and Post-COVID Lungs.

Authors:  Emanuele Pontali; Denise Rossato Silva; Florian M Marx; Jose Antonio Caminero; Rosella Centis; Lia D'Ambrosio; Jose Maria Garcia-Garcia; Jeremiah Chakaya Muhwa; Simon Tiberi; Giovanni Battista Migliori
Journal:  Arch Bronconeumol       Date:  2022-06-10       Impact factor: 6.333

4.  Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations.

Authors:  Emmanuel André; Bouke C de Jong; Kamela C S Ng; Armand van Deun; Conor J Meehan; Gabriela Torrea; Michèle Driesen; Siemon Gabriëls; Leen Rigouts
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

5.  Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts.

Authors:  Vidya Mave; Jonathan E Golub; Samyra R Cox; Abhay Kadam; Sachin Atre; Akshay N Gupte; Hojoon Sohn; Nikhil Gupte; Trupti Sawant; Vishal Mhadeshwar; Ryan Thompson; Emily Kendall; Christopher Hoffmann; Nishi Suryavanshi; Deanna Kerrigan; Srikanth Tripathy; Arjunlal Kakrani; Madhusudan S Barthwal
Journal:  Trials       Date:  2022-08-05       Impact factor: 2.728

6.  Surface-Shaving Proteomics of Mycobacterium marinum Identifies Biofilm Subtype-Specific Changes Affecting Virulence, Tolerance, and Persistence.

Authors:  Kirsi Savijoki; Henna Myllymäki; Hanna Luukinen; Lauri Paulamäki; Leena-Maija Vanha-Aho; Aleksandra Svorjova; Ilkka Miettinen; Adyary Fallarero; Teemu O Ihalainen; Jari Yli-Kauhaluoma; Tuula A Nyman; Mataleena Parikka
Journal:  mSystems       Date:  2021-06-22       Impact factor: 6.496

Review 7.  [New vaccines against tuberculosis].

Authors:  Stefan H E Kaufmann
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-01       Impact factor: 1.513

Review 8.  Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology.

Authors:  Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2020-02-27       Impact factor: 7.561

9.  Tuberculosis recurrences and predictive factors in a vulnerable population in Catalonia.

Authors:  Sílvia Brugueras; Vinicio-Israel Molina; Xavier Casas; Yoel-Domingo González; Nuria Forcada; Dora Romero; Anna Rodés; Maria-Neus Altet; José Maldonado; Mario Martin-Sánchez; Joan A Caylà; Àngels Orcau; Cristina Rius; Joan-Pau Millet
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

10.  Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hainan, China: from 2014 to 2019.

Authors:  Lin Liu; Xiujuan Zhao; Xingyong Wu; Sijing Li; Biao Liu; Mamy Jayne Nelly Rajaofera; Yingfei Zeng; Sufang Dong; Zheng Bei; Hua Pei; Qianfeng Xia
Journal:  BMC Microbiol       Date:  2021-06-19       Impact factor: 3.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.